loading page

Therapy-related mixed phenotype acute leukemia in a pediatric survivor of Ewing sarcoma with a novel RUNX1-TAF3 fusion: A case report and review of the literature
  • Madhav Vissa,
  • Cheryl Peretz,
  • Jennifer Michlitsch
Madhav Vissa
UCSF Benioff Children's Hospital Oakland
Author Profile
Cheryl Peretz
UCSF Benioff Children's Hospital Oakland
Author Profile
Jennifer Michlitsch
UCSF Benioff Children's Hospital Oakland
Author Profile

Abstract

Increasing treatment intensity for pediatric Ewing sarcoma (ES) has improved survival, but comes with an increased incidence of secondary malignancy. Here, we describe a case of therapy-related mixed phenotype acute leukemia (t-MPAL), T-myeloid type, in a pediatric patient four years after completion of therapy for ES. Genomic evaluation revealed a novel and likely pathogenic RUNX1-TAF3 fusion. This patient did not respond to T-cell leukemia-directed therapy, and while he initially responded to myeloid leukemia-directed therapy, he never achieved complete remission and died of disease 10 months after diagnosis. Here, we present this case and review prior literature regarding t-MPAL.